Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Therapeutic T cell engineering

Nature volume 545, pages 423–431 (2017)Cite this article

Subjects

Abstract

Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of synthetic receptors that reprogram lymphocyte specificity and function. CARs targeting CD19 have demonstrated remarkable potency in B cell malignancies. Engineered T cells are applicable in principle to many cancers, pending further progress to identify suitable target antigens, overcome immunosuppressive tumour microenvironments, reduce toxicities, and prevent antigen escape. Advances in the selection of optimal T cells, genetic engineering, and cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infectious diseases and autoimmunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Receptors for antigen.
Figure 2: Where to apply CAR therapy.
Figure 3: Therapeutic T cell design: goals and strategies.
Figure 4: Cell sources for T cell engineering.

Similar content being viewed by others

References

  1. Miller, J. F. Immunological function of the thymus. Lancet 2, 748–749 (1961)

    Article  CAS  PubMed  Google Scholar 

  2. Jorgensen, J. L., Reay, P. A., Ehrich, E. W. & Davis, M. M. Molecular components of T-cell recognition. Annu. Rev. Immunol. 10, 835–873 (1992)

    Article  CAS  PubMed  Google Scholar 

  3. Mitchison, N. A. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102, 157–177 (1955)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Klein, G., Sjogren, H. O., Klein, E. & Hellstrom, K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561–1572 (1960)

    CAS  PubMed  Google Scholar 

  5. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281–355 (1991)

    Article  CAS  PubMed  Google Scholar 

  6. Melief, C. J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143–175 (1992)

    Article  CAS  PubMed  Google Scholar 

  7. Old, L. J. Tumor immunology: the first century. Curr. Opin. Immunol. 4, 603–607 (1992)

    Article  CAS  PubMed  Google Scholar 

  8. Rosenberg, S. A. & Lotze, M. T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 4, 681–709 (1986)

    Article  CAS  PubMed  Google Scholar 

  9. Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318–1321 (1986)

    Article  ADS  CAS  PubMed  Google Scholar 

  10. Weiden, P. L. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068–1073 (1979)

    Article  CAS  PubMed  Google Scholar 

  11. Martin, P. J. & Kernan, N. A. in Graft vs. Host Disease: Immunology, Pathophysiology, and Treatment (eds Burkoff, S. J., Deeg, H. J., Ferrara, J. & Atkinson, K. ) 371–387 (Marcel Dekker, New York, 1990)

  12. Riddell, S. R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238–241 (1992)

    Article  ADS  CAS  PubMed  Google Scholar 

  13. Kolb, H. J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86, 2041–2050 (1995)

    Article  CAS  PubMed  Google Scholar 

  14. Riddell, S. R. & Greenberg, P. D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545–586 (1995)

    Article  CAS  PubMed  Google Scholar 

  15. Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994)

    Article  CAS  PubMed  Google Scholar 

  16. Heslop, H. E., Brenner, M. K. & Rooney, C. M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679–680 (1994)

    Article  CAS  PubMed  Google Scholar 

  17. Sadelain, M. in Encyclopedia of Immunobiology (ed. Ratcliffe, M. J. H. ) Vol. 4 (Elsevier Academic Press, 2016)

  18. Miller, A. D. Retrovirus packaging cells. Hum. Gene Ther. 1, 5–14 (1990)

    Article  CAS  PubMed  Google Scholar 

  19. Sadelain, M. & Mulligan, R. C. in 8th International Congress of Immunolog (ed. International Congress of Immunology) (Springer-Verlag, Budapest; Hungary, 1992)

  20. Sadelain, M., Rivière, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003)

    Article  CAS  PubMed  Google Scholar 

  21. Ho, W. Y., Blattman, J. N., Dossett, M. L., Yee, C. & Greenberg, P. D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3, 431–437 (2003)

    Article  CAS  PubMed  Google Scholar 

  22. Dembicć, Z. et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320, 232–238 (1986)

    Article  ADS  Google Scholar 

  23. Clay, T. M. et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163, 507–513 (1999)

    CAS  PubMed  Google Scholar 

  24. Stone, J. D., Harris, D. T. & Kranz, D. M. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr. Opin. Immunol. 33, 16–22 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133–151 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cameron, B. J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Voss, R. H. et al. Molecular design of the Cαβ interface favors specific pairing of introduced TCRαβ in human T cells. J. Immunol. 180, 391–401 (2008)

    Article  CAS  PubMed  Google Scholar 

  28. Bialer, G., Horovitz-Fried, M., Ya’acobi, S., Morgan, R. A. & Cohen, C. J. Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 184, 6232–6241 (2010)

    Article  CAS  PubMed  Google Scholar 

  29. Stone, J. D. et al. A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. CII 63, 1163–1176 (2014)

    CAS  PubMed  Google Scholar 

  30. Ochi, T. et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 118, 1495–1503 (2011)

    Article  CAS  PubMed  Google Scholar 

  31. Robbins, P. F . et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).TCR-engineered T cells induce antigen-specific responses in patients with melanoma or sarcoma.

    Article  CAS  PubMed  Google Scholar 

  32. Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914–921 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sadelain, M., Brentjens, R. & Rivière, I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215–223 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891–901 (1991)

    Article  CAS  PubMed  Google Scholar 

  35. Romeo, C. & Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037–1046 (1991)

    Article  CAS  PubMed  Google Scholar 

  36. Letourneur, F. & Klausner, R. D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl Acad. Sci. USA 88, 8905–8909 (1991)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  37. Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  38. Brocker, T., Peter, A., Traunecker, A. & Karjalainen, K. New simplified molecular design for functional T cell receptor. Eur. J. Immunol. 23, 1435–1439 (1993)

    Article  CAS  PubMed  Google Scholar 

  39. Brocker, T. & Karjalainen, K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181, 1653–1659 (1995)

    Article  CAS  PubMed  Google Scholar 

  40. Gong, M. C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123–127 (1999)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Brocker, T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96, 1999–2001 (2000)

    Article  CAS  PubMed  Google Scholar 

  42. Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619–626 (1998)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hombach, A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 167, 6123–6131 (2001)

    Article  CAS  PubMed  Google Scholar 

  44. Maher, J ., Brentjens, R. J ., Gunset, G ., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002).Human T cells expressing a second-generation CAR expand and remain functional upon repeated exposure to antigen.

    Article  CAS  PubMed  Google Scholar 

  45. Jensen, M. C. & Riddell, S. R. Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33, 9–15 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hinrichs, C. S. & Restifo, N. P. Reassessing target antigens for adoptive T-cell therapy. Nat. Biotechnol. 31, 999–1008 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6, 133–146 (2016)

    Article  CAS  PubMed  Google Scholar 

  48. van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499–509 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415–428 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380–390 (2016)

    Article  CAS  PubMed  Google Scholar 

  51. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013)

    Article  CAS  PubMed  Google Scholar 

  52. Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J. & Jensen, M. C. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51, 263–272 (2012)

    Article  CAS  PubMed  Google Scholar 

  53. Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Jackson, H . et al. Using CAR T Cells to Deliver Immune Modulating Agents Directly to the Tumor Microenvironment. (The New York Academy of Sciences, 2016)

  56. Zhou, X. et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 125, 4103–4113 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Paszkiewicz, P. J. et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J. Clin. Invest. 126, 4262–4272 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  58. Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003).Human T cells engineered to express a CD19-specific CAR eradicate systemic B cell malignancies in mice.

    Article  CAS  PubMed  Google Scholar 

  59. Engel, P. et al. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3, 39–50 (1995)

    Article  CAS  PubMed  Google Scholar 

  60. Rickert, R. C., Rajewsky, K. & Roes, J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376, 352–355 (1995)

    Article  ADS  CAS  PubMed  Google Scholar 

  61. Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875–3886 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8, e61338 (2013)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  64. Lamers, C. H. et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72–82 (2011)

    Article  CAS  PubMed  Google Scholar 

  65. Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26–31 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Kochenderfer, J. N . et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).First report of a clinical response to CD19 CAR therapy in non-Hodgkin lymphoma.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Kalos, M . et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).First report of clinical response to CD19 in CAR therapy in chronic lymphocytic leukaemia.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Brentjens, R. J . et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).First report of clinical responses to CD19 CAR therapy in acute lymphoblastic leukaemia.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Sadelain, M. CAR therapy: the CD19 paradigm. J. Clin. Invest. 125, 3392–3400 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  70. Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015)

    Article  CAS  PubMed  Google Scholar 

  72. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015)

    Article  CAS  PubMed  Google Scholar 

  75. Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  76. Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Couzin-Frankel, J. Cancer immunotherapy. Science 342, 1432–1433 (2013)

    Article  ADS  CAS  PubMed  Google Scholar 

  79. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  80. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. June, C. H., Riddell, S. R. & Schumacher, T. N. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7, 280ps7 (2015)

    Article  PubMed  CAS  Google Scholar 

  82. Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Anti-CD22 CAR therapy leads to ALL remissions. Cancer Discov. 7, 120 http://dx.doi.org/10.1158/2159-8290.CD-NB2017-001 (2017)

  84. Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ali, S. A . et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688–1700 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  87. Lu, Y. C. & Robbins, P. F. Targeting neoantigens for cancer immunotherapy. Int. Immunol. 28, 365–370 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Stewart-Jones, G. et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc. Natl Acad. Sci. USA 106, 5784–5788 (2009)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  89. Zhang, G. et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci. Rep. 4, 3571 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  90. Oren, R. et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J. Immunol. 193, 5733–5743 (2014)

    Article  CAS  PubMed  Google Scholar 

  91. Inaguma, Y. et al. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther. 21, 575–584 (2014)

    Article  CAS  PubMed  Google Scholar 

  92. Maus, M. V. et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol. Ther. 3, 16023 (2017)

    Google Scholar 

  93. Balakrishnan, A. et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin. Cancer Res. (2016)

  94. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81–85 (1997)

    CAS  PubMed  Google Scholar 

  95. Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006)

    Article  PubMed  Google Scholar 

  96. Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011)

    Article  CAS  PubMed  Google Scholar 

  97. Johnson, L. A. et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-Cell Therapy. N. Engl. J. Med. 375, 2561–2569 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505–3518 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75, 3596–3607 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Duong, C. P., Westwood, J. A., Berry, L. J., Darcy, P. K. & Kershaw, M. H. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 3, 33–48 (2011)

    Article  CAS  PubMed  Google Scholar 

  103. Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059–1070 (2012)

    Article  CAS  PubMed  Google Scholar 

  104. Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. ADDENDUM: T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 639–641 (2016)

    Article  PubMed  Google Scholar 

  105. Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036–3052 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  106. Wu, C. Y ., Roybal, K. T ., Puchner, E. M ., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015)

    Article  ADS  PubMed  PubMed Central  CAS  Google Scholar 

  107. Sun, J. & Sadelain, M. The quest for spatio-temporal control of CAR T cells. Cell Res. 25, 1281–1282 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  108. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  109. Wrzesinski, C. et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33, 1–7 (2010)

    Article  PubMed  PubMed Central  Google Scholar 

  110. Munn, D. H. Blocking IDO activity to enhance anti-tumor immunity. Front. Biosci. (Elite Ed.) 4, 734–745 (2012)

    Article  Google Scholar 

  111. Ramsay, A. G., Clear, A. J., Fatah, R. & Gribben, J. G. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120, 1412–1421 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Young, A., Mittal, D., Stagg, J. & Smyth, M. J. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4, 879–888 (2014)

    Article  CAS  PubMed  Google Scholar 

  113. Ruella, M. et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31, 246–248 (2017)

    Article  CAS  PubMed  Google Scholar 

  114. Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130–3144 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  115. Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR) modified T cells and induces tumor regression: refueling the CAR. Blood 129, 1039–1041 (2017)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013)

    Article  CAS  PubMed  Google Scholar 

  117. Condomines, M. et al. Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition. PLoS One 10, e0130518 (2015)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Menger, L. et al. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors. Cancer Res. 76, 2087–2093 (2016)

    Article  CAS  PubMed  Google Scholar 

  119. Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160–1170 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Markley, J. C. & Sadelain, M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508–3519 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672–1683 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Stephan, M. T. et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440–1449 (2007)

    Article  CAS  PubMed  Google Scholar 

  123. Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671–684 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Farber, D. L., Yudanin, N. A. & Restifo, N. P. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14, 24–35 (2014)

    Article  CAS  PubMed  Google Scholar 

  125. Buchholz, V. R. et al. Disparate individual fates compose robust CD8+ T cell immunity. Science 340, 630–635 (2013)

    Article  ADS  CAS  PubMed  Google Scholar 

  126. Gerlach, C. et al. Heterogeneous differentiation patterns of individual CD8+ T cells. Science 340, 635–639 (2013)

    Article  ADS  CAS  PubMed  Google Scholar 

  127. Graef, P. et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8+ central memory T cells. Immunity 41, 116–126 (2014)

    Article  CAS  PubMed  Google Scholar 

  128. Busch, D. H., Fräßle, S. P., Sommermeyer, D., Buchholz, V. R. & Riddell, S. R. Role of memory T cell subsets for adoptive immunotherapy. Semin. Immunol. 28, 28–34 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616–1626 (2005)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294–305 (2008)

    Article  CAS  PubMed  Google Scholar 

  131. Hinrichs, C. S. et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl Acad. Sci. USA 106, 17469–17474 (2009)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  132. Turtle, C. J. et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  133. Stemberger, C. et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS One 7, e35798 (2012)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  134. van der Waart, A. B. et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 124, 3490–3500 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Kagoya, Y. et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 126, 3479–3494 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  136. Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519–528 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129–4139 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112–1121 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Jacoby, E. et al. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361–1370 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Ghosh, A. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23, 242–249 (2017)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Yang, L. & Baltimore, D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc. Natl Acad. Sci. USA 102, 4518–4523 (2005)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  142. Zakrzewski, J. L. et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat. Biotechnol. 26, 453–461 (2008)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Melenhorst, J. J. et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116, 4700–4702 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. O’Reilly, R. J., Prockop, S., Hasan, A. N., Koehne, G. & Doubrovina, E. Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections. Bone Marrow Transplant. 51, 1163–1172 (2016)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113–5123 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965–2973 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807–815 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697–5705 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Berdien, B., Mock, U., Atanackovic, D. & Fehse, B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 21, 539–548 (2014)

    Article  CAS  PubMed  Google Scholar 

  150. Qasim, W . et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).Talen-mediated TCR deletion enables CD19 CAR therapy with donor T cells in allogeneic recipients.

    Article  PubMed  Google Scholar 

  151. Timmermans, F. et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J. Immunol. 182, 6879–6888 (2009)

    Article  CAS  PubMed  Google Scholar 

  152. Vizcardo, R. et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 12, 31–36 (2013)

    Article  CAS  PubMed  Google Scholar 

  153. Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114–126 (2013)

    Article  CAS  PubMed  Google Scholar 

  154. Themeli, M . et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928–933 (2013).Human CAR T cells generated in vitro from pluripotent stem cells induce tumour regression in mice.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Themeli, M., Rivière, I. & Sadelain, M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16, 357–366 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Singh, H., Huls, H., Kebriaei, P. & Cooper, L. J. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol. Rev. 257, 181–190 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Zhao, Y. et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13, 151–159 (2006)

    Article  CAS  PubMed  Google Scholar 

  158. Birkholz, K. et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 16, 596–604 (2009)

    Article  CAS  PubMed  Google Scholar 

  159. Eyquem, J . et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).CRISPR–Cas9-mediated CAR delivery to the TCR locus delays T cell differentiation and exhaustion of CAR T cells resulting in improved CAR T cell therapeutic efficacy.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  160. Wang, X. & Rivière, I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 22, 85–94 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Chiou, P. Y., Ohta, A. T. & Wu, M. C. Massively parallel manipulation of single cells and microparticles using optical images. Nature 436, 370–372 (2005)

    Article  ADS  CAS  PubMed  Google Scholar 

  162. Kennedy, D. R., Gerhardson, T., Sporbert, B., Mealey, D., Rust, M. J. & Lipkens, B. The Concentration and separation of blood components using acoustic radiation force. Blood 122, 3665 (2013)

    Article  Google Scholar 

  163. Urbansky, A., Lenshof, A., Dykes, J., Laurell, T. & Scheding, S. Separation of lymphocyte populations from peripheral blood progenitor cell products using affinity bead acoustophoresis. Blood 124, 315–315 (2014)

    Article  Google Scholar 

  164. Jesuraj, N. J. et al. A novel phase-change hydrogel substrate for t cell activation promotes increased expansion of CD8+ cells expressing central memory and naive phenotype markers. Blood 128, 3368–3368 (2016)

    Article  Google Scholar 

  165. Cieri, N. et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573–584 (2013)

    Article  CAS  PubMed  Google Scholar 

  166. Chapuis, A. G. et al. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J. Clin. Oncol. 34, 3787–3795 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Kaiser, A. D. et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 22, 72–78 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Roh, K. H., Nerem, R. M. & Roy, K. Biomanufacturing of therapeutic cells: state of the art, current challenges, and future perspectives. Annu. Rev. Chem. Biomol. Eng. 7, 455–478 (2016)

    Article  CAS  PubMed  Google Scholar 

  169. Deeks, S. G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5, 788–797 (2002)

    Article  CAS  PubMed  Google Scholar 

  170. DuPage, M. & Bluestone, J. A. Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease. Nat. Rev. Immunol. 16, 149–163 (2016)

    Article  CAS  PubMed  Google Scholar 

  171. Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016).CAR T cells can treat autoimmunity in a murine model of pemphigus vulgaris.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  172. Lee, J. C. et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71, 2871–2881 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Blat, D., Zigmond, E., Alteber, Z., Waks, T. & Eshhar, Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol. Ther. 22, 1018–1028 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Boardman, D. A. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am. J. Transplant. 17, 931–943 (2017)

    Article  CAS  PubMed  Google Scholar 

  175. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the National Cancer Institute for supporting their research via grants R01 CA114536; R01 CA136551; P01 CA59350 and P30 CA008748.

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, 10065, New York, USA

    Michel Sadelain & Isabelle Rivière

  2. Fred Hutchinson Cancer Research Center, Seattle, 98109, Washington, USA

    Stanley Riddell

Authors
  1. Michel Sadelain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Rivière
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley Riddell
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.S., I.R. and S.R. co-authored the review.

Corresponding author

Correspondence to Michel Sadelain.

Ethics declarations

Competing interests

S.R., I.R. and M.S. are consultants for Juno Therapeutics.

Additional information

Reviewer Information Nature thanks C. Melief, N. Restifo and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423–431 (2017). https://doi.org/10.1038/nature22395

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature22395

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer